|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 234.90 DKK | -36.38% |
|
-35.43% | -49.64% |
| 07/03 | Health Care Down, but not by Much, Amid Defensive Bias - Health Care Roundup | DJ |
| 06/03 | KBC Securities Downgrades Zealand Pharma to Accumulate, Cuts PT | MT |
| Capitalization | 16.59B 2.57B 2.22B 2B 1.92B 3.51B 237B 3.67B 23.69B 9.49B 113B 9.66B 9.46B 406B | P/E ratio 2026 * |
13.8x | P/E ratio 2027 * | -29.7x |
|---|---|---|---|---|---|
| Enterprise value | 4.45B 691M 596M 538M 516M 941M 63.49B 985M 6.36B 2.55B 30.45B 2.59B 2.54B 109B | EV / Sales 2026 * |
1.01x | EV / Sales 2027 * | 1.6x |
| Free-Float |
99.18% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Zealand Pharma A/S
| 1 day | -36.38% | ||
| 1 week | -35.43% | ||
| Current month | -35.43% | ||
| 1 month | -42.33% | ||
| 3 months | -53.76% | ||
| 6 months | -47.57% | ||
| Current year | -49.64% |
| 1 week | 234.9 |  | 376 |
| 1 month | 234.9 | | 428 |
| Current year | 234.9 | | 478.5 |
| 1 year | 234.9 | | 725 |
| 3 years | 205.6 | | 972 |
| 5 years | 69.55 | | 972 |
| 10 years | 69.55 | | 972 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 30/03/2022 | |
| Director of Finance/CFO | - | 01/11/2022 | |
David Kendall
CTO | Chief Tech/Sci/R&D Officer | 64 | 02/06/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | - | |
Kirsten Drejer
BRD | Director/Board Member | 69 | 19/04/2018 |
| Director/Board Member | 67 | 04/04/2019 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +0.20% | 0% | 50 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -36.38% | -35.43% | -55.97% | -0.30% | 2.57B | |
| -0.61% | -5.35% | +12.03% | +92.93% | 44.16B | |
| +0.92% | -4.81% | +49.26% | +14.90% | 40.5B | |
| -2.40% | -6.16% | +87.11% | +608.08% | 30.21B | |
| -0.44% | -7.92% | -6.69% | -21.33% | 25.47B | |
| +2.54% | -9.65% | +53.01% | -34.70% | 19.22B | |
| -2.62% | -6.49% | +4.16% | -31.60% | 16.5B | |
| +5.20% | +0.37% | +47.19% | +154.57% | 12.64B | |
| +1.14% | -8.92% | -15.02% | +994.93% | 11.72B | |
| +4.43% | -0.31% | +55.98% | - | 11.51B | |
| Average | -2.82% | -8.11% | +23.11% | +197.50% | 21.45B | |
| Weighted average by Cap. | -0.15% | -5.53% | +32.61% | +172.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.39B 681M 587M 530M 508M 927M 62.56B 970M 6.26B 2.51B 30B 2.55B 2.5B 107B | 3.5B 543M 468M 422M 405M 739M 49.89B 774M 4.99B 2B 23.92B 2.04B 1.99B 85.56B |
| Net income | 1.27B 197M 170M 154M 147M 269M 18.15B 281M 1.82B 728M 8.7B 741M 725M 31.12B | -787M -122M -105M -95.12M -91.27M -166M -11.23B -174M -1.12B -451M -5.39B -459M -449M -19.26B |
| Net Debt | -12.14B -1.88B -1.62B -1.47B -1.41B -2.57B -173B -2.68B -17.33B -6.94B -83.02B -7.07B -6.92B -297B | -10.98B -1.7B -1.47B -1.33B -1.27B -2.32B -157B -2.43B -15.69B -6.28B -75.13B -6.4B -6.26B -269B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/03/26 | 234.90 kr | -36.38% | 3,364,160 |
| 05/03/26 | 369.20 kr | -0.62% | 155,917 |
| 04/03/26 | 371.50 kr | +4.21% | 190,858 |
| 03/03/26 | 356.50 kr | -2.94% | 255,939 |
| 02/03/26 | 367.30 kr | +0.96% | 208,631 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ZEAL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition